Niagen Bioscience (NAGE)
Builds Niagen-based supplements, ingredients, and clinical NAD+ channels.
$3.06
vs last close−0.03 (−0.91%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Insiders | 1.35% | 1.08M shares | |
|---|---|---|---|
| 3 holders · as of Jul 8, 2026 | |||
| Other | 98.65% | 78.57M shares | |
| remainder | |||
79.64M company shares as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
13F
No 13F holders on record.
13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Nov 14, 2025 | Ozan Pamirofficer: Chief Financial Officer | Purchase · 2 lots | 6,685 | $6.82 | 9,593 |
House and Senate disclosures
Not reported.